At AI Therapeutics, we are focused on identifying and developing treatments for rare orphan conditions. We use a variety of methods to identify promising assets to add to our pipeline. Our current clinical stage drug candidates target several orphan disorders including pulmonary sarcoidosis, bronchiolitis obliterans post lung transplant, pulmonary arterial hypertension, and amyotrophic lateral sclerosis.
